Table 2.
Pooled effects obtained in meta-analysis models for delta body weight gain at 20 d.
| CI 95% |
|||||
|---|---|---|---|---|---|
| Challenge | Treatment | Pooled effects (%) | Lower | Upper | I2 and P-value heterogeneity |
| E. acervulina | Overall | 6.52 | 2.21 | 10.8 | 0%, P = 1.0 |
| Lasalocid | 9.08 | −2.39 | 20.5 | 0%, P = 0.7 | |
| Maduramycin | 2.08 | −10.3 | 14.4 | 0%, P = 0.9 | |
| Decoquinate | 13.95 | −0.79 | 28.6 | 0%, P = 0.8 | |
| Nicarbazin+semduramicin | 7.89 | −5.20 | 20.9 | 0%, P = 0.7 | |
| Monensin | 3.90 | −5.22 | 13.0 | 0%, P = 0.3 | |
| Salinomycin | 5.72 | −8.06 | 19.5 | 0%, P = 0.7 | |
| Narasin+Nicarbazin | 7.07 | −7.29 | 21.4 | 0%, P = 0.6 | |
| Nicarbazin | 6.57 | −5.18 | 18.3 | 0%, P = 0.8 | |
| E. maxima | Overall | 5.25 | −1.12 | 11.6 | 0%, P = 1.0 |
| Lasalocid | 10.35 | −10.9 | 31.6 | 0%, P = 0.7 | |
| Maduramycin | 5.02 | −20.2 | 30.2 | 0%, P = 0.9 | |
| Decoquinate | 9.84 | −8.22 | 27.9 | 0%, P = 0.5 | |
| Nicarbazin+semduramicin | 3.47 | −15.1 | 22.1 | 0%, P = 0.9 | |
| Monensin | 3.10 | −12.8 | 19.0 | 0%, P = 0.9 | |
| Salinomycin | 3.97 | −12.5 | 20.4 | 0%, P = 0.7 | |
| Narasin+Nicarbazin | 3.73 | −15.6 | 23.1 | 0%, P = 0.8 | |
| Nicarbazin | 4.71 | −9.95 | 19.4 | 0%, P = 0.8 | |
CI: Confidence interval; I2: I-square test percentual and P-value of this. I-square is a heterogeneity test that evaluates if the differences between measures are random or more than expected. When heterogeneity is significant (I-square > 70–0% and/or P < 0.05), random effect models were used to calculate pooled effect. When not significant, fixed effect models were used. This procedure is necessary not to validate the results obtained, but to validate methods used to combine them. Significant or not significant differences between pooled effects of each compound can be evaluated by comparing confidence intervals and their intersections. Significant differences are when there is no intersections between CI.